|
WO2013096744A1
(en)
|
2011-12-21 |
2013-06-27 |
Novira Therapeutics, Inc. |
Hepatitis b antiviral agents
|
|
EA038942B1
(ru)
*
|
2012-08-28 |
2021-11-12 |
Янссен Сайенсиз Айрлэнд Юси |
Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
|
|
CN105209031A
(zh)
*
|
2012-12-27 |
2015-12-30 |
德雷克塞尔大学 |
针对hbv感染的新型抗病毒剂
|
|
HUE034820T2
(en)
|
2013-02-28 |
2018-02-28 |
Janssen Sciences Ireland Uc |
Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
|
|
EA027068B1
(ru)
|
2013-04-03 |
2017-06-30 |
Янссен Сайенсиз Айрлэнд Юси |
Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
|
|
TWI651300B
(zh)
|
2013-05-17 |
2019-02-21 |
健生科學愛爾蘭無限公司 |
胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
|
|
DK3024819T3
(en)
|
2013-07-25 |
2018-06-06 |
Janssen Sciences Ireland Uc |
GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
|
|
KR102290189B1
(ko)
|
2013-10-23 |
2021-08-17 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
JP6553059B2
(ja)
*
|
2014-02-05 |
2019-07-31 |
ノヴィラ・セラピューティクス・インコーポレイテッド |
Ｈｂｖ感染の治療のための併用療法
|
|
WO2015118057A1
(en)
|
2014-02-06 |
2015-08-13 |
Janssen Sciences Ireland Uc |
Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
PT3116316T
(pt)
|
2014-03-13 |
2019-09-30 |
Assembly Biosciences Inc |
Moduladores alostéricos da proteína do núcleo da hepatite b
|
|
US9400280B2
(en)
|
2014-03-27 |
2016-07-26 |
Novira Therapeutics, Inc. |
Piperidine derivatives and methods of treating hepatitis B infections
|
|
CA2948580A1
(en)
*
|
2014-05-09 |
2015-11-12 |
Adam Zlotnick |
Methods and compositions for treating hepatitis b virus infections
|
|
US9597332B2
(en)
|
2014-12-02 |
2017-03-21 |
Novira Therapeutics, Inc. |
Sulfide alkyl compounds for HBV treatment
|
|
WO2016089990A1
(en)
|
2014-12-02 |
2016-06-09 |
Novira Therapeutics, Inc. |
Sulfide alkyl and pyridyl reverse sulfonamide compounds for hbv treatment
|
|
MA41140A
(fr)
*
|
2014-12-12 |
2017-10-17 |
Cancer Research Tech Ltd |
Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
|
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
|
WO2016107832A1
(en)
|
2014-12-30 |
2016-07-07 |
F. Hoffmann-La Roche Ag |
Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
|
|
US9765050B2
(en)
|
2014-12-30 |
2017-09-19 |
Novira Therapeutics, Inc. |
Pyridyl reverse sulfonamides for HBV treatment
|
|
EP3271019A1
(en)
*
|
2015-03-19 |
2018-01-24 |
Novira Therapeutics Inc. |
Azocane and azonane derivatives and methods of treating hepatitis b infections
|
|
US10442788B2
(en)
|
2015-04-01 |
2019-10-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2016177655A1
(en)
*
|
2015-05-04 |
2016-11-10 |
F. Hoffmann-La Roche Ag |
Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
|
|
US10738035B2
(en)
|
2015-05-13 |
2020-08-11 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
US10179131B2
(en)
|
2015-07-13 |
2019-01-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
TWI730985B
(zh)
|
2015-09-15 |
2021-06-21 |
美商艾森伯利生物科學公司 |
B型肝炎核心蛋白質調節劑
|
|
HK1259410A1
(zh)
|
2015-09-29 |
2019-11-29 |
诺维拉治疗公司 |
乙型肝炎抗病毒剂的晶体形式
|
|
JP6904970B2
(ja)
|
2016-03-07 |
2021-07-21 |
エナンタ ファーマシューティカルズ インコーポレイテッド |
Ｂ型肝炎抗ウイルス剤
|
|
SG10202011827YA
(en)
|
2016-04-15 |
2021-01-28 |
Novira Therapeutics Inc |
Combinations and methods comprising a capsid assembly inhibitor
|
|
CA3026252A1
(en)
*
|
2016-06-03 |
2017-12-07 |
University Of Tennessee Research Foundation |
Autotaxin inhibitors
|
|
CN109843296A
(zh)
|
2016-06-10 |
2019-06-04 |
英安塔制药有限公司 |
乙型肝炎抗病毒药剂
|
|
EP3500294A4
(en)
|
2016-08-22 |
2020-07-29 |
Arbutus Biopharma Corporation |
ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
WO2018052967A1
(en)
*
|
2016-09-13 |
2018-03-22 |
Arbutus Biopharma, Inc. |
Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
|
|
AU2017326356A1
(en)
|
2016-09-15 |
2019-04-11 |
Assembly Biosciences, Inc. |
Hepatitis B core protein modulators
|
|
TWI794190B
(zh)
|
2016-11-07 |
2023-03-01 |
加拿大商愛彼特生物製藥公司 |
含有取代的吡啶酮之三環化合物及其使用方法
|
|
EA037576B1
(ru)
*
|
2016-11-11 |
2021-04-15 |
Новира Терапьютикс, Инк. |
Комбинации и способы, включающие ингибитор сборки капсида
|
|
AU2018217664B2
(en)
*
|
2017-02-07 |
2022-03-03 |
Janssen Pharmaceutica Nv |
Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis
|
|
RU2650610C1
(ru)
|
2017-02-28 |
2018-04-16 |
Васильевич Иващенко Александр |
Противовирусная композиция и способ ее применения
|
|
SG11201908012SA
(en)
|
2017-03-02 |
2019-09-27 |
Assembly Biosciences Inc |
Cyclic sulfamide compounds and methods of using same
|
|
AU2018238138A1
(en)
|
2017-03-21 |
2019-10-17 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
|
|
CN110869017B
(zh)
|
2017-05-12 |
2023-05-05 |
英安塔制药有限公司 |
细胞凋亡信号调节激酶1抑制剂及其使用方法
|
|
KR20200020887A
(ko)
|
2017-06-27 |
2020-02-26 |
얀센 파마슈티카 엔.브이. |
헤테로아릴디히드로피리미딘 유도체 및 b형 간염 감염의 치료 방법
|
|
US10513515B2
(en)
|
2017-08-25 |
2019-12-24 |
Biotheryx, Inc. |
Ether compounds and uses thereof
|
|
US10952978B2
(en)
*
|
2017-08-28 |
2021-03-23 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2019046186A1
(en)
|
2017-08-28 |
2019-03-07 |
Enanta Pharmaceuticals, Inc. |
INHIBITORS OF KINASE 1 REGULATING THE APOPTOTIC SIGNAL CONTAINING TETRAZOLES AND METHODS OF USE THEREOF
|
|
TW201912153A
(zh)
*
|
2017-08-30 |
2019-04-01 |
加拿大商愛彼特生物製藥公司 |
用於治療ｂ型肝炎的化合物、醫藥組合物及方法
|
|
TW201936192A
(zh)
|
2017-12-06 |
2019-09-16 |
美商因那塔製藥公司 |
B 型肝炎抗病毒試劑
|
|
TW201927789A
(zh)
|
2017-12-06 |
2019-07-16 |
美商因那塔製藥公司 |
B型肝炎抗病毒試劑
|
|
US11058678B2
(en)
|
2018-01-22 |
2021-07-13 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
PL3759109T3
(pl)
|
2018-02-26 |
2024-03-04 |
Gilead Sciences, Inc. |
Podstawione związki pirolizyny jako inhibitory replikacji hbv
|
|
CA3090125A1
(en)
|
2018-03-14 |
2019-09-19 |
Janssen Sciences Ireland Unlimited Company |
Capsid assembly modulator dosing regimen
|
|
WO2019191166A1
(en)
|
2018-03-29 |
2019-10-03 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2019206072A1
(zh)
*
|
2018-04-24 |
2019-10-31 |
浙江海正药业股份有限公司 |
磺酰胺芳基甲酰胺衍生物及其制备方法和用途
|
|
EP3787621B1
(en)
|
2018-05-02 |
2024-12-18 |
Enanta Pharmaceuticals, Inc. |
Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
|
|
WO2019213239A1
(en)
*
|
2018-05-02 |
2019-11-07 |
Enanta Pharmaceuticals Inc. |
Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
|
|
EP3597653A1
(en)
|
2018-07-19 |
2020-01-22 |
Irbm S.P.A. |
Cyclic inhibitors of hepatitis b virus
|
|
EP3597637A1
(en)
*
|
2018-07-19 |
2020-01-22 |
Irbm S.P.A. |
Inhibitors of hepatitis b virus
|
|
AU2019309894A1
(en)
|
2018-07-27 |
2021-01-28 |
Biotheryx, Inc. |
Bifunctional compounds as CDK modulators
|
|
TWI869058B
(zh)
|
2018-07-27 |
2025-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
US11053235B2
(en)
|
2018-08-09 |
2021-07-06 |
Janssen Sciences Ireland Unlimited Company |
Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
|
|
EP3608326A1
(en)
|
2018-08-10 |
2020-02-12 |
Irbm S.P.A. |
Tricyclic inhibitors of hepatitis b virus
|
|
US10968199B2
(en)
|
2018-08-22 |
2021-04-06 |
Enanta Pharmaceuticals, Inc. |
Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
|
|
UY38383A
(es)
|
2018-09-21 |
2020-04-30 |
Enanta Pharm Inc |
Heterociclos funcionalizados como agentes antivirales
|
|
BR112021006403A2
(pt)
*
|
2018-10-05 |
2021-07-06 |
Univ Emory |
agentes monômeros e multiméricos anti-hbv
|
|
TW202028190A
(zh)
|
2018-10-22 |
2020-08-01 |
美商艾森伯利生物科學公司 |
用於治療hbv之5員雜芳甲醯胺化合物
|
|
US20210395751A1
(en)
|
2018-10-31 |
2021-12-23 |
The University Of Sydney |
Compositions and methods for treating viral infections
|
|
WO2020106707A1
(en)
|
2018-11-19 |
2020-05-28 |
Enanta Pharmaceuticals, Inc. |
Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
|
|
US11198693B2
(en)
|
2018-11-21 |
2021-12-14 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
TW202415643A
(zh)
|
2018-12-12 |
2024-04-16 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
WO2020163479A1
(en)
*
|
2019-02-05 |
2020-08-13 |
Board Of Regents, The University Of Texas System |
Antibiotic ammonium compounds and methods for the treatment of bacterial infections
|
|
MX2021010145A
(es)
|
2019-02-22 |
2021-09-14 |
Janssen Sciences Ireland Unlimited Co |
Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
|
|
US11466033B2
(en)
|
2019-03-25 |
2022-10-11 |
Enanta Pharmaceuticals, Inc. |
Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
|
|
MA55879A
(fr)
|
2019-05-06 |
2022-03-16 |
Janssen Sciences Ireland Unlimited Co |
Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
|
|
EP3825318A1
(en)
|
2019-11-25 |
2021-05-26 |
Promidis S.r.l. |
Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
|
|
EP3741762A1
(en)
|
2019-05-23 |
2020-11-25 |
Irbm S.P.A. |
Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
|
|
UY38705A
(es)
|
2019-05-23 |
2020-12-31 |
Irbm S P A |
Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b
|
|
SG11202112590WA
(en)
|
2019-05-24 |
2021-12-30 |
Assembly Biosciences Inc |
Pharmaceutical compositions for the treatment of hbv
|
|
WO2020247444A1
(en)
|
2019-06-03 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
|
WO2020247561A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
|
WO2020247575A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2020255013A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
|
|
US11738019B2
(en)
|
2019-07-11 |
2023-08-29 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
US11236108B2
(en)
|
2019-09-17 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
AU2020355000A1
(en)
|
2019-09-23 |
2022-03-17 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein B (APOB) gene expression
|
|
CN114729376A
(zh)
|
2019-09-23 |
2022-07-08 |
欧米茄治疗公司 |
用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法
|
|
AU2020408039A1
(en)
|
2019-12-20 |
2022-08-18 |
Arbutus Biopharma Corporation |
Synthetic processes and intermediates
|
|
CN116096886A
(zh)
|
2020-03-11 |
2023-05-09 |
欧米茄治疗公司 |
用于调节叉头框p3(foxp3)基因表达的组合物和方法
|
|
WO2021188414A1
(en)
|
2020-03-16 |
2021-09-23 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocyclic compounds as antiviral agents
|
|
KR20210126507A
(ko)
|
2020-04-10 |
2021-10-20 |
주식회사 스탠다임 |
벤즈아미드 화합물을 포함하는 암 예방 또는 치료용 조성물
|
|
CN111349056B
(zh)
*
|
2020-04-16 |
2022-08-02 |
南京安纳康生物科技有限公司 |
用于乙型肝炎病毒感染的抗病毒剂
|
|
CN111393391B
(zh)
*
|
2020-04-16 |
2022-07-26 |
南京安纳康生物科技有限公司 |
用于乙型肝炎病毒感染的抗病毒剂
|
|
WO2021216660A1
(en)
|
2020-04-22 |
2021-10-28 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of hbv
|
|
CA3180706A1
(en)
|
2020-04-22 |
2021-10-28 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of hbv
|
|
WO2021216661A1
(en)
|
2020-04-22 |
2021-10-28 |
Assembly Biosciences, Inc. |
Pyrazole carboxamide compounds for treatment of hbv
|
|
US20230295096A1
(en)
|
2020-04-22 |
2023-09-21 |
Assembly Biosciences, Inc. |
Pyrazole carboxamide compounds for treatment of hbv
|
|
US11897930B2
(en)
|
2020-04-28 |
2024-02-13 |
Anwita Biosciences, Inc. |
Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
|
|
JP7675182B2
(ja)
*
|
2020-11-10 |
2025-05-12 |
フォグホーン セラピューティクス インコーポレイテッド |
化合物及びその使用
|
|
EP4367242A2
(en)
|
2021-07-07 |
2024-05-15 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
WO2023069547A1
(en)
|
2021-10-20 |
2023-04-27 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of hbv
|
|
WO2023069545A1
(en)
|
2021-10-20 |
2023-04-27 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of hbv
|
|
WO2023069544A1
(en)
|
2021-10-20 |
2023-04-27 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of hbv
|
|
KR102617049B1
(ko)
|
2021-12-30 |
2023-12-21 |
장고옥 |
헤어고데기
|
|
WO2023164186A1
(en)
|
2022-02-25 |
2023-08-31 |
Assembly Biosciences, Inc. |
Benzothia(dia)zepine compounds for treatment of hbv and hdv
|
|
WO2023164179A1
(en)
|
2022-02-25 |
2023-08-31 |
Assembly Biosciences, Inc. |
Benzothia(dia)zepine compounds for treatment of hbv and hdv
|
|
WO2023164181A1
(en)
|
2022-02-25 |
2023-08-31 |
Assembly Biosciences, Inc. |
Benzothia(dia)zepine compounds for treatment of hbv and hdv
|
|
WO2023164183A1
(en)
|
2022-02-25 |
2023-08-31 |
Assembly Biosciences, Inc. |
Benzothia(dia)zepine compounds for treatment of hbv and hdv
|
|
AR128846A1
(es)
|
2022-03-23 |
2024-06-19 |
Ideaya Biosciences Inc |
Compuestos de indazol sustituidos con piperazina como inhibidores de parg
|
|
WO2024029481A1
(ja)
*
|
2022-08-01 |
2024-02-08 |
国立研究開発法人理化学研究所 |
抗ｈｂｖ剤
|
|
JP2025529185A
(ja)
*
|
2022-08-30 |
2025-09-04 |
パンネックス セラピューティクス インコーポレイテッド |
パネキシン－１調節剤及びパネキシン－１が関与する疾患の治療方法
|
|
CN115677545B
(zh)
*
|
2022-10-28 |
2024-03-15 |
潍坊医学院 |
一种抗hbv磺胺苯甲酰胺类衍生物及其制备方法和应用
|
|
CN116410106B
(zh)
*
|
2023-04-13 |
2024-12-06 |
山东第二医科大学 |
一种苯甲酰胺类hbv衣壳蛋白抑制剂及其制备方法与应用
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
WO2025043094A1
(en)
|
2023-08-23 |
2025-02-27 |
Assembly Biosciences, Inc. |
Benzothia(dia)zepine compounds for treatment of hbv and hdv
|
|
WO2026038156A1
(en)
|
2024-08-15 |
2026-02-19 |
Assembly Biosciences, Inc. |
Novel crystalline forms
|